ALPMY News and Press, Astellas Pharma Inc. ADR From 12/15/22

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers PR Newswire Astellas' GLOW trial, the se...

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers PR Newswire Astellas' SPOTLIGHT trial me...

Astellas Pharma Inc. (ALPMF) Q3 2022 Earnings Conference Call October 31, 2022 04:00 a.m. ET Company Representatives Kenji Yasukawa - Chief Executive Officer Yoshitsugu Shitaka - CScO, Chief Scientific Officer Minoru Kikuoka - Chief Financial Officer Tadaaki ...

Summary Riding two powerful franchises (Iomab and Actimab), Actinium Pharmaceuticals is brewing a deep pipeline of therapeutics for multiple indications. There is also AWE Technology that is developed in collaboration with other biotech innovators. The best time to consider pi...

Japan's Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) is acquiring a 15% stake in Taysha Gene Therapies ( NASDAQ: TSHA ) for $50M to support the advancement of Taysha's gene therapy programs for Rett syndrome and giant axonal neuropathy (GAN). Un...

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs PR Newswire - Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing ...

Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting PR Newswire SKYLIGHT 4™ study results demonstrate the 52-week safety and tolerability of fezolinetant 30 ...

Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) and Pantherna Therapeutics signed a new technology evaluation agreement to research on generating mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation). The agreement expand...

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming PR Newswire TOKYO and HENNIGSDORF, Germany , Oct. 3, 2022 ...

The European Medicines Agency (EMA) accepted to review Astellas Pharma's ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) application seeking approval of oral drug fezolinetant to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, commonly called hot...